Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 Transmission from Presymptomatic Meeting Attendee, Germany.
Hijnen D, Marzano AV, Eyerich K, GeurtsvanKessel C, Giménez-Arnau AM, Joly P, Vestergaard C, Sticherling M, Schmidt E. Hijnen D, et al. Among authors: eyerich k. Emerg Infect Dis. 2020 Aug;26(8):1935-1937. doi: 10.3201/eid2608.201235. Epub 2020 May 11. Emerg Infect Dis. 2020. PMID: 32392125 Free PMC article.
Global Allergy Forum and 3rd Davos Declaration 2015: Atopic dermatitis/Eczema: challenges and opportunities toward precision medicine.
Bieber T, Akdis C, Lauener R, Traidl-Hoffmann C, Schmid-Grendelmeier P, Schäppi G, Allam JP, Apfelbacher C, Augustin M, Beck L, Biedermann T, Braun-Fahrländer C, Chew FT, Clavel T, Crameri R, Darsow U, Deleuran M, Dittlein D, Duchna HW, Eichenfeld L, Eyerich K, Frei R, Gelmetti C, Gieler U, Gilles S, Glatz M, Grando K, Green J, Gutermuth J, Guttman-Yassky E, Hanifin J, Hijnen D, Hoetzenecker W, Irvine A, Kalweit A, Katoh N, Knol E, Koren H, Möhrenschlager M, Münch D, Novak N, O'Mahony L, Paller AS, Rhyner C, Roduit C, Schiesser K, Schröder J, Simon D, Simon HU, Sokolowska M, Spuls P, Stalder JF, Straub D, Szalai Z, Taieb A, Takaoka R, Todd G, Todorova A, Vestergaard C, Werfel T, Wollenberg A, Ring J. Bieber T, et al. Among authors: eyerich k. Allergy. 2016 May;71(5):588-92. doi: 10.1111/all.12857. Epub 2016 Mar 8. Allergy. 2016. PMID: 27023268 No abstract available.
45th meeting of the Arbeitsgemeinschaft Dermatologische Forschung.
Loser K, Eming R, Eyerich K, Gebhardt C, Ludwig R, Baghin V, Baurecht H, Forsthuber A, Glodde N, Schmidt E, Schmidt T, Shridhar N, Simon B, Gaffal E. Loser K, et al. Among authors: eyerich k. Exp Dermatol. 2018 Jul;27(7):798-802. doi: 10.1111/exd.13695. Exp Dermatol. 2018. PMID: 29953698 No abstract available.
Human and computational models of atopic dermatitis: A review and perspectives by an expert panel of the International Eczema Council.
Eyerich K, Brown SJ, Perez White BE, Tanaka RJ, Bissonette R, Dhar S, Bieber T, Hijnen DJ, Guttman-Yassky E, Irvine A, Thyssen JP, Vestergaard C, Werfel T, Wollenberg A, Paller AS, Reynolds NJ. Eyerich K, et al. J Allergy Clin Immunol. 2019 Jan;143(1):36-45. doi: 10.1016/j.jaci.2018.10.033. Epub 2018 Nov 7. J Allergy Clin Immunol. 2019. PMID: 30414395 Free PMC article. Review.
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K. Thaçi D, et al. Among authors: eyerich k. Br J Dermatol. 2020 Aug;183(2):265-275. doi: 10.1111/bjd.18696. Epub 2020 Jan 20. Br J Dermatol. 2020. PMID: 31705526 Clinical Trial.
EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis.
Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong PY, O'Mahony L, Schwarze J, Warner A, Werfel T, Palomares O, Jutel M. Agache I, et al. Among authors: eyerich k. Allergy. 2021 Apr;76(4):988-1009. doi: 10.1111/all.14690. Epub 2020 Dec 27. Allergy. 2021. PMID: 33538044
EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old.
Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong PY, O'Mahony L, Schwarze J, Warner A, Werfel T, Palomares O, Jutel M. Agache I, et al. Among authors: eyerich k. Allergy. 2022 Jan;77(1):17-38. doi: 10.1111/all.15030. Epub 2021 Aug 8. Allergy. 2022. PMID: 34324716
A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE).
Pinter A, Hoffmann M, Reich K, Augustin M, Kaplan K, Gudjónsdóttir SD, Delvin T, Mrowietz U; CHANGE investigator group. Pinter A, et al. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):701-711. doi: 10.1111/jdv.16932. Epub 2020 Dec 23. J Eur Acad Dermatol Venereol. 2021. PMID: 32939860 Clinical Trial.
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines.
Agache I, Rocha C, Pereira A, Song Y, Alonso-Coello P, Solà I, Beltran J, Posso M, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong P, O'Mahony L, Schwarze J, Werfel T, Canelo-Aybar C, Palomares O, Jutel M. Agache I, et al. Among authors: eyerich k. Allergy. 2021 Jan;76(1):59-70. doi: 10.1111/all.14547. Epub 2020 Sep 7. Allergy. 2021. PMID: 32767573
226 results